Multidrug-resistant Gram-negative infections: The use of colistin

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 9, 2010, Pages 1009-1017

  Michalopoulos, Argyris S ^a   Karatza, Dimitra C ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Acinetobacter baumannii; antibiotic resistance; colistimethate sodium; colistin; Gram negative bacteria; Klebsiella pneumoniae; multidrug resistant pathogens; polymyxin; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; COLISTIMETHATE; COLISTIN; DIURETIC AGENT; GENTAMICIN; POLYMYXIN; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER INFECTION; ATAXIA; BACTEREMIA; BRAIN VENTRICULITIS; BRONCHOSPASM; CATHETER INFECTION; CHEST TIGHTNESS; COMBINATION CHEMOTHERAPY; CONFUSION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; FEVER; GASTROINTESTINAL DISEASE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; HYPERSENSITIVITY REACTION; KLEBSIELLA PNEUMONIAE INFECTION; MENINGITIS; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PERITONITIS; PNEUMONIA; PRURITUS; PSEUDOMEMBRANOUS COLITIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN INFECTION; URINARY TRACT INFECTION; URTICARIA; VENTILATOR ASSOCIATED PNEUMONIA; VERTIGO; WEAKNESS; WOUND INFECTION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL;

EID: 77956481087     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.88     Document Type: Review

References (90)

1. Wadl M, Heckenbach K, Noll I et al. Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German University Hospitals, 2002-2006. Infection 38, 47-51 (2010).
2. Samuelsen O, Toleman MA, Sundsfjord A et al. Molecular epidemiology of metallo-b-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob. Agents Chemother. 54(1), 346-352 (2010).
3. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents 35(3), 240-243 (2010).
4. Kohlenberg A, Schwab F, Meyer E, Behnke M, Geffers C, Gastmeier P. Regional trends in multidrug-resistant infections in German intensive care units: a real-time model for epidemiological monitoring and analysis. J. Hosp. Infect. 73(3), 239-245 (2009).
5. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn. Microbiol. Infect. Dis. 66(1), 78-86 (2010).
6. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin. Pharmacother. 11(5), 779-788 (2010).
7. Mesaros N, Nordmann P, Plésiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13(6), 560-578 (2007). (Pubitemid 46730662)
8. McGowan JE Jr. Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum. Am. J. Infect. Control. 34(5 Suppl. 1), S29-S37 (2006).
9. Butler MS, Buss AD. Natural products-the future scaffolds for novel antibiotics? Biochem. Pharmacol. 71, 919-929 (2006).
10. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit. Care Clin. 24(2), 377-391 (2008).
11. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10(1), R27 (2006).
12. Falagas ME, Rafailidis PI, Ioannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 35(2), 194-199 (2010).
13. Nation RL, Li J. Colistin in the 21st Century. Curr. Opin Infect. Dis. 22(6), 535-543 (2009).
14. Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am. J. Health Syst. Pharm. 64(23), 2462-2466 (2007).
15. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J. Antimicrob. Chemother. 39(2), 255-260 (1997).
16. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res. 4(2), 138-146 (2006).
17. Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, Baziaka F, Karagianni V, Giamarellou H. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol Infect. Dis. 57, 419-422 (2007).
18. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fbrosis. Antimicrob. Agents Chemother. 45(3), 781-785 (2001).
19. Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 64(12), 4922-4927 (1996).
20. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti Infect. Ther. 5, 811-821 (2007).
21. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother. 33, 960-967 (1999).
22. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 3471-3484 (2007).
23. Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case-control study. Crit. Care Med. 36(3), 807-811 (2008).
24. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J. Chemother. 15(3), 235-238 (2003).
25. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25, 11-25 (2005).
26. Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of colistin (polymyxin E) against 3,480 isolates of Gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob. Agents Chemother. 53(11), 4924-4926 (2009).
27. Galani I, Kontopidou F, Souli M et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int. J. Antimicrob. Agents 31(5), 434-439 (2008).
28. Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen PH. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 51(10), 3726-3730 (2007).
29. Tan TY, Ng LS. Comparison of three standardized disc susceptibility testing methods for colistin. J. Antimicrob Chemother. 58(4), 864-867 (2006).
30. Tan TY, Ng SY Comparison of Etest, VITEK and agar dilution for susceptibility testing of colistin. Clin. Microbiol. Infect. 13(5), 541-544 (2007).
31. Somily AM. Comparison of E-test and disc diffusion methods for the in vitro evaluation of the antimicrobial activity of colistin in multi-drug resistant Gram-negative bacilli. Saudi Med. J. 31(5), 507-511 (2010).
32. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 11(2), 115-121 (2005).
33. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 53(8), 3430-3436 (2009).
34. Papagelopoulos PJ, Mavrogenis AF, Giannitsioti E, Kikilas A, Kanellakopoulou K, Soucacos PN. Management of a multidrug-resistant Pseudomonas aeruginosa infected total knee arthroplasty using colistin. A case report and review of the literature. J. Arthroplasty 22(3), 457-463 (2007).
35. Westerman EM, Le Brun PPH, Touw DJ, Frijlink HW, Heijerman HGM. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fbrosis: a pilot study. J. Cyst. Fibros. 3, 23-28 (2004).
36. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26(6), 504-507 (2007).
37. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37(11), e154-e160 (2003).
38. Kohlenberg A, Weitzel-Kage D, van der Linden P et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit. J. Hosp. Infect. 74(4), 350-357 (2010).
39. Glupczynski Y, Bogaerts P, Deplano A et al. Detection and characterization of class A extended-spectrum-b-lactamase-producing Pseudomonas aeruginosa isolates in Belgian hospitals. J. Antimicrob. Chemother. 65(5), 866-871 (2010).
40. Viedma E, Juan C, Acosta J et al. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum b-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 53(11), 4930-4933 (2009).
41. Rosanova M, Epelbaum C, Noman A et al. Use of colistin in a pediatric burn unit in Argentina. J. Burn Care Res. 30(4), 612-615 (2009).
42. Montero M, Horcajada JP, Sorlí L et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 37(5), 461-465 (2009).
43. Sabuda DM, Laupland K, Pitout J et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can. J. Infect. Dis. Med. Microbiol. 19(6), 413-418 (2008).
44. Kallel H, Hergaf L, Bahloul M et al. Safety and effcacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 33(7), 1162-1167 (2007).
45. Rios FG, Luna CM, Maskin B et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur. Respir. J. 30(2), 307-313 (2007).
46. Falagas ME, Agrafotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev. Anti Infect. Ther. 6(4), 447-452 (2008).
47. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant Gram (-) nosocomial pneumonia: a case series. Respir. Med. 103(5), 707-713 (2009).
48. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg. Infect. (Larchmt) 9(2), 153-160 (2008).
49. Nasnas R, Saliba G, Hallak P. [The revival of colistin: an old antibiotic for the 21st Century]. Pathol. Biol. (Paris) 57(3), 229-235 (2009).
50. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14(9), 816-827 (2008).
51. Yakupogullari Y, Otlu B, Dogukan M et al. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa. Am. J. Infect. Control 36(10), e13-e18 (2008).
52. Santamaría C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P. Nephrotoxicity associated with the use of intravenous colistin. Scand. J. Infect. Dis. 41(10), 767-769 (2009).
53. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and effcacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int. J. Antimicrob. Agents 35(3), 297-300 (2010).
54. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30(1), 143-151 (2008).
55. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Effcacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int. J. Infect. Dis. 11(5), 402-406 (2007).
56. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int. J. Antimicrob. Agents 34(5), 434-438 (2009).
57. Keen EF 3rd, Robinson BJ, Hospenthal DR et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns 36(6), 819-825 (2010).
58. Monterrubio-Villar J, González-Velasco C, Valdezate-Ramos S et al. Outbreak of multiresistant Acinetobacter baumannii in a polyvalent intensive care unit: clinical, epidemiological analysis and PFGE-printing evolution. Eur. J. Clin. Microbiol. Infect. Dis. 28(10), 1281-1284 (2009).
59. Touati A, Achour W, Cherif A et al. Outbreak of Acinetobacter baumannii in a neonatal intensive care unit: antimicrobial susceptibility and genotyping analysis. Ann. Epidemiol. 19(6), 372-378 (2009).
60. Jean SS, Hsueh PR, Lee WS et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int. J. Antimicrob. Agents 33(3), 266-271 (2009).
61. Canduela MJ, Gallego L, Sevillano E, Valderrey C, Calvo F, Pérez J. Evolution of multidrug-resistant Acinetobacter baumannii isolates obtained from elderly patients with respiratory tract infections. J. Antimicrob. Chemother. 57(6), 1220-1222 (2006).
62. Gordona NC, Warehamab DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int. J. Antimicrob. Agents 35(3), 219-226 (2010).
63. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2), S49-S56 (2006).
64. Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 61(2), 417-420 (2008).
65. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53(4), 274-278 (2006).
66. Maviglia R, Nestorini R, Pennisi M. Role of old antibiotics in multidrug resistant bacterial infections. Curr. Drug Targets 10(9), 895-905 (2009).
67. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R et al. Effcacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54(3), 1165-1172 (2010).
68. Cirioni O, Ghiselli R, Orlando F et al. Effcacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit. Care Med. 35(7), 1717-1723 (2007).
69. Katsaragakis S, Markogiannakis H, Toutouzas KG et al. Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance. World J. Surg. 32(6), 1194-1202 (2008).
70. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin. Pharmacother. 9(4), 587-599 (2008).
71. Routsi C, Pratikaki M, Platsouka E et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 38(3), 173-180 (2010).
72. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Saroglou G, Geroulanos S. Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units. Eur. J. Cardiothorac. Surg. 33(6), 1086-1090 (2008).
73. Samra Z, Ofr O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int. J. Antimicrob. Agents 30(6), 525-529 (2007).
74. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30(7), 666-671 (2009).
75. Souli M, Galani I, Antoniadou A et al. An outbreak of infection due to b-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin. Infect. Dis. 50(3), 364-373 (2010).
76. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-b-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53(5), 1868-1872 (2009).
77. Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH. Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. Antimicrob. Agents Chemother. 54(1), 560-562 (2010).
78. Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: frst report of a multiclonal cluster. J. Antimicrob. Chemother. 59(4), 786-790 (2007).
79. Zarkotou O, Pournaras S, Voulgari E et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J. Clin. Microbiol. DOI: 10.1128/JCM.02301-09 (2010) (Epub ahead of print).
80. Pintado V, San Miguel LG, Grill F et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J. Infect. 56(3), 185-190 (2008).
81. Lu Q, Girardi C, Zhang M et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 36(7), 1147-1155 (2010).
82. Berlana D, Llop JM, Fort E, Badia MB, Jódar R. Use of colistin in the treatment of multiple-drug-resistant Gram-negative infections. Am. J. Health Syst. Pharm. 62(1), 39-47 (2005).
83. Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Resp. Med. 102, 407-412 (2008).
84. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin. Microbiol. Infect. 16(8), 1230-1236 (2010).
85. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant Gram (-) nosocomial pneumonia: a case series. Respir. Med. 103(5), 707-713 (2009).
86. Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJ. Risk factors for infections related to external ventricular drainage. Acta Neurochir. (Wien) 150, 209-214 (2008).
87. Ng J, Gosbell IB, Kelly JA, Boyle MJ Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J. Antimicrob. Chemother. 58(5), 1078-1081 (2006).
88. Cascio A, Conti A, Sinardi L et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int. J. Infect. Dis. 14(7), e572-e579 (2010).
89. Rodríguez Guardado A, Blanco A, Asensi V et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J. Antimicrob. Chemother. 61, 908-913 (2008).
90. Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J. Clin. Microbiol. 43, 4916-4917 (2005).